Evaluation of COVID-19 mortality and adverse outcomes in US patients with or without cancer
JAMA Nov 03, 2021
Chavez-MacGregor M, Lei X, Zhao H, et al. - Researchers performed comparisons between patients with COVID-19 with or without cancer with respect to the rates of death, mechanical ventilation, intensive care unit stay, and hospitalization.
Using the Optum de-identified COVID-19 electronic health record data set, a cohort study of more than 500,000 US adults who were diagnosed with COVID-19 was performed.
Outcomes revealed an increased risk of death, intensive care unit admission, and hospitalization among patients with cancer who received anticancer treatment within 3 months before COVID-19 diagnosis.
Similar or better outcomes were recorded for patients without recent cancer treatment when compared with those without cancer.
Overall findings have risk stratification as well as resource use implications for patients, clinicians, and health systems.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries